Eliminate HIV

Ending the HIV epidemic as a public health threat is now a real possibility.

Globally, an estimated 37.7 million people were living with HIV, with 74 percent on life-saving antiretroviral treatment, according to UNAIDS.

In Australia, more than 29,000 people were living with HIV in 2020 with an estimated 1 in 10 people unaware of their HIV-positive status. According to annual HIV surveillance data, there were 633 new HIV diagnoses in 2020, representing a decline of 37 per cent over the previous five years.

Burnet’s HIV research uses a multifaceted approach and focuses on four pillars towards eliminating HIV:

  • Prevention and vaccines
  • Testing
  • Modelling and surveillance
  • Treatment and quality of life

The goals of our Eliminate HIV program include:

  • Facilitating reductions in new HIV infections in Australia and internationally through an improved understanding of the major drivers of transmission.
  • Working towards HIV elimination by addressing key barriers to the implementation of evidence-based HIV prevention programs, and expanding access to HIV diagnosis and treatment.
  • Using basic, discovery and translational research to develop, trial and implement new strategies and tools that assist in the prevention, diagnosis and treatment of HIV.

Download

Contact Details

Chad Hughes

Head of International Development; Director, Mekong

Telephone

+61392822214

Email

chad.hughes@burnet.edu.au


Projects

  • A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression

  • A GIFT (Genital Inflammation Test) for HIV Prevention

  • A novel gel for targeting vaginal inflammation to prevent HIV transmission

  • ACCESS: The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmitted Infections

  • Ageing Well with HIV

  • Antimicrobial and immune modulatory effects of vaginal microbiota metabolites

  • Assessing the feasibility of an integrated HIV cascade of care surveillance system in Myanmar (ACCESS Myanmar)

  • Broadly neutralising anti-HIV antibodies and Fc Receptor function

  • Community-Based Rapid HIV Testing Services

  • DARE C: ATAHC II Substudy

  • Decision science using Optima

  • Depo Provera and Beyond

  • Development of a novel prophylactic vaccine candidate for HIV-1

  • Development of hydrogel based intravaginal drug delivery device

  • EVE-M

  • Getting to the heart of cardiovascular disease in HIV

  • HIV Prevention Cohort

  • Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility

  • Mucosal injury from sexual contact (MISC)

  • Optima HIV Modelling

  • Predicting quality and potency of monoclonal and natural antibodies

  • PrEPX: Rapid scale-up of HIV pre-exposure prophylaxis (PrEP)

  • Project Geldom

  • PRONTO! Rapid HIV point-of-care testing in Victoria

  • SHARP: Sexual Health And Risk Prevention Study

  • Stellabody® Technology in Infectious Disease – COVID-19 and beyond

  • Tackling TB and HIV Together in Papua New Guinea

  • TAIPAN: HIV cascade surveillance

  • Targeting HIV-infected macrophages to achieve an HIV cure

  • Targeting novel sites on reverse transcriptase for HIV treatment and prevention

  • The persistence of HIV in monocytes and macrophages

  • The role of female genital tract microbial function in inflammation and HIV infection risk.

Latest News